Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.

Panelists discuss how minimal residual disease assessment demonstrates superior depth of response with ciltacabtagene autoleucel compared with standard of care in patients who have ...

Panelists discuss how adding a fourth drug (daratumumab) to standard triplet induction therapy may improve outcomes for patients with newly diagnosed, transplant-eligible multiple myeloma.

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...

Saeed Sadeghi, MD, discusses valuable feedback he heard from oncologists on the use of luspatercept-aamt in patients with low-risk myelodysplastic syndrome.

Akriti Jain, MD, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition.

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Pancreatic ductal adenocarcinoma remains a challenge to treat due to its complex biology and resistance mechanisms.

During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients ...

Alfa, MD, discusses the findings and key takeaways from the SUMMIT trial, which evaluated the use of neratinib for the ...

Knowing whether repurposing old drugs helps patients with cancer is important, but it will take a concerted investment by public entities such as the National Institutes of Health to make this happen.